568 related articles for article (PubMed ID: 15699107)
1. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
2. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
Qi L; Rojas JM; Ostrand-Rosenberg S
J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
[TBL] [Abstract][Full Text] [Related]
3. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
4. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
[TBL] [Abstract][Full Text] [Related]
5. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells.
Adorini L; Guéry JC; Fuchs S; Ortiz-Navarrete V; Hämmerling GJ; Momburg F
J Immunol; 1993 Oct; 151(7):3576-86. PubMed ID: 7690807
[TBL] [Abstract][Full Text] [Related]
6. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.
Oxenius A; Bachmann MF; Ashton-Rickardt PG; Tonegawa S; Zinkernagel RM; Hengartner H
Eur J Immunol; 1995 Dec; 25(12):3402-11. PubMed ID: 8566030
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
8. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.
Frauwirth K; Shastri N
Immunology; 2001 Apr; 102(4):405-15. PubMed ID: 11328374
[TBL] [Abstract][Full Text] [Related]
9. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent.
Tewari MK; Sinnathamby G; Rajagopal D; Eisenlohr LC
Nat Immunol; 2005 Mar; 6(3):287-94. PubMed ID: 15711549
[TBL] [Abstract][Full Text] [Related]
10. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
Albert LJ; Ghumman B; Watts TH
J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
[TBL] [Abstract][Full Text] [Related]
11. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
12. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
15. The extracellular domains of MHC class II molecules determine their processing requirements for antigen presentation.
Kjer-Nielsen L; Perera JD; Boyd LF; Margulies DH; McCluskey J
J Immunol; 1990 Apr; 144(8):2915-24. PubMed ID: 1969876
[TBL] [Abstract][Full Text] [Related]
16. Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.
Becker HJ; Kondo E; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon MS
Eur J Haematol; 2016 Aug; 97(2):166-74. PubMed ID: 26561366
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
18. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins.
Sanderson S; Frauwirth K; Shastri N
Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7217-21. PubMed ID: 7638170
[TBL] [Abstract][Full Text] [Related]
19. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
20. The class II MHC-restricted presentation of endogenously synthesized ovalbumin displays clonal variation, requires endosomal/lysosomal processing, and is up-regulated by heat shock.
Michalek MT; Benacerraf B; Rock KL
J Immunol; 1992 Feb; 148(4):1016-24. PubMed ID: 1737924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]